Safety and Efficacy of IMCnyeso in Advanced NY-ESO-1 and/or LAGE-1A Positive Cancers
NCT03515551
·
clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
TERMINATED
Status
29
Enrollment
INDUSTRY
Sponsor class
Stopped
Strategic decision to stop development and not based on any safety concerns
Conditions
Select Advanced Solid Tumors
Interventions
DRUG:
IMCnyeso
Sponsor
Immunocore Ltd